HPS2560-95
78362-34-2
默认>95%HPLC，若需其他规格请洽询
| 产品编号 | 规格 | 货期 | 销售价 | 折扣价 | 数量 | 操作 |
|---|---|---|---|---|---|---|
| HPS2560-95 | 默认>95%HPLC，若需其他规格请洽询 |
25天
|
敬请询价 | 敬请询价 |
 
|
| 名字 | Copeptin (human) trifluoroacetate salt |
|---|---|
| 序列(三字母) | H-Ala-Ser-Asp-Arg-Ser-Asn-Ala-Thr-Gln-Leu-Asp-Gly-Pro-Ala-Gly-Ala-Leu-Leu-Leu-Arg-Leu-Val-Gln-Leu-Ala-Gly-Ala-Pro-Glu-Pro-Phe-Glu-Pro-Ala-Gln-Pro-Asp-Ala-Tyr-OH trifluoroacetate salt |
| 序列(单字母) | ASDRSNATQLDGPAGALLLRLVQLAGAPEPFEPAQPDAY |
| CAS# | 78362-34-2 |
| 分子式 | C₁₇₇H₂₇₉N₄₉O₅₈ |
| 分子量 | 4021.46 |
| 纯度 | 默认>95%HPLC，若需其他规格请洽询 |
| 合成方法 | Synthetic |
| 储存条件 | -20 ± 5 °C |
| 应用 | Cardiovascular System & Diseases |
| 描述 | Copeptin (CT-proAVP) is initially produced in equimolar amounts to (Arg⁸)-Vasopressin (AVP). Due to the high stability of copeptin in plasma and serum its measurement is not affected by the problems, which are associated with the direct measurement of AVP, and thus, is suitable to indirectly determine the release of AVP. Copeptin has emerged as a prognostic marker in a variety of diseases, such as sepsis, community-acquired pneumonia, chronic obstructive pulmonary failure, heart failure and myocardial infarction. |
